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Vitamin D receptor: A highly 
versatile nuclear receptor
JR Wu-Wong1
Vitamin D receptor (VDR) modulators are used to treat 
hyperparathyroidism secondary to chronic kidney disease (CKD). 
The therapy is associated with reduced mortality in stage 5 CKD 
patients, who experience an extremely high cardiovascular disease 
(CVD)-related mortality rate. Chen et al. report that VDR is involved 
in regulating type A natriuretic peptide receptor (NPR-A) in inner 
medullary collecting duct cells.   The regulation of NPR-A may be 
one of several mechanisms by which VDR activation reduces CVD risk 
in CKD.
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Introduction
Vitamin D3 is made from 7-dehydro-
cholesterol in the skin aft er exposure 
to ultraviolet light and is modified 
by vitamin D3-25-hydroxylase in the 
liver and then by 25-hydroxyvitamin 
D3-1α-hydroxylase (CYP27B1) that 
resides mainly in the proximal renal 
tubule to form the active hormone, 
1,25-dihydroxyvitamin D3 (calcitriol). 
Calcitriol exerts its functions via bind-
ing to a nuclear receptor, the vitamin D 
receptor (VDR). Th e binding of calci-
triol to VDR activates the receptor to 
recruit cofactors to form a complex that 
binds to vitamin D response elements 
in the promoter region of target genes 
to regulate gene transcription. During 
the past three decades, the main focus 
in the VDR fi eld has been to elucidate its 
role in regulating mineral homeostasis. 
Consequently, calcitriol and its ana-
logues, such as alfacalcidol, doxercalcif-
erol, and paricalcitol, are used clinically 
for the treatment of hyperparathy-
roidism secondary to chronic kidney 
disease (CKD).
VDR modulator therapy associated with 
survival benefit in chronic kidney disease
It is well documented that stage 3 to stage 
5 CKD patients encounter a much higher 
risk of cardiovascular disease (CVD) 
than the general public and experience 
an extremely high CVD-related mortality 
rate. Recent clinical observations, albeit 
retrospective, found that VDR modulator 
therapy is associated with a survival benefi t 
for stage 5 CKD patients. Kalantar-Zadeh 
et al.1 showed in 2006 that, in a 2-year 
cohort of 58,058 maintenance hemodialy-
sis patients, administration of any dose of 
paricalcitol was associated with improved 
survival in time-varying models. Tentori et 
al.2 showed that, in a 5-year cohort of 7,731 
hemodialysis patients, doxercalciferol treat-
ment was also associated with improved 
survival. Two previous reports by Teng et 
al.3,4 demonstrated very similar fi ndings. 
Furthermore, the survival benefi t of VDR 
modulator therapy may be independent 
of calcium, phosphorous, and parathyroid 
hormone levels in the patients. How is 
VDR modulator therapy associated with a 
survival benefi t in stage 5 CKD? What are 
the possible mechanisms? Unfortunately, 
so far the answers remain elusive.
Cardiovascular phenotype in VDR knock-
out mice
VDR has been identified in more than 
30 diff erent tissues in the human body, 
including adipose tissue, bone marrow, 
cardiomyocytes, the immune system’s 
B and T lymphocytes, renal cells, and 
vascular smooth muscle cells, implying 
that VDR may be involved in regulating 
a variety of biophysiological functions 
besides mineral homeostasis. Indeed, VDR 
knockout mice, in addition to the expected 
phenotype (such as abnormal mineral 
homeostasis), developed hypertension and 
exhibited increased water consumption 
and urinary salt excretion. Subsequently, 
it was shown that the size of left  ventricu-
lar cardiomyocytes in VDR knockout mice 
was markedly increased when compared 
with that in wild-type mice, and levels of 
atrial natriuretic peptide (ANP) mRNA 
and circulating ANP were also increased 
in VDR knockout mice.5 In addition, the 
thrombomodulin gene in the aorta, liver, 
and kidney of VDR knockout mice was 
downregulated, and tissue factor mRNA 
expression in the liver and kidney was 
upregulated independent of plasma cal-
cium levels, suggesting that VDR may play 
roles in regulating fi brinolysis and throm-
bogenesis.6 Judging from recent publica-
tions in the VDR fi eld, the role of VDR 
activation in the cardiovascular system is 
becoming an important research area.
VDR modulates atrial natriuretic peptide 
and its receptor
Th e group led by Gardner at the Univer-
sity of California at San Francisco has 
been active in investigating VDR-medi-
ated cardiovascular functions for many 
years. Th ey have previously reported that 
VDR is expressed in cardiomyocytes, 
and activation of VDR leads to reduced 
hypertrophy and suppression of ANP 
expression and secretion in cardiomyo-
cytes treated with endothelin-1.7 Th ey 
have also shown that calcitriol amplifi es 
type A natriuretic peptide receptor (NPR-
A) expression in rat aortic smooth muscle 
cells.8 In addition, in rats treated with a 
VDR modulator and infused with ANP, 
the NPR-A mRNA levels in the inner 
medulla were significantly increased, 
along with an increase in urinary cyclic 
guanosine monophosphate levels, uri-
nary sodium, and urine volume. Follow-
ing those studies, the group now reports 
(Chen et al.,9 this issue) that both VDR 
and CYP27B1 are expressed in cultured 
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inner medullary collecting duct cells, and 
that treatment of these cells with VDR 
modulators results in an increase in the 
NPR-A protein level and in ANP-depend-
ent cyclic guanosine monophosphate 
production, while mutation of a vitamin 
D response element upstream of the 
NPR-A gene results in the loss of VDR-
mediated NPR-A induction.
Th ese new fi ndings are important in 
that they help us understand more about 
VDR, a seemingly very versatile nuclear 
receptor, and its involvement in the car-
diovascular system, including regulation 
of NPR-A. NPR-A is a receptor consist-
ing of a large extracellular ligand-binding 
domain, a single membrane-spanning 
segment, and an intracellular signaling 
domain with a non-catalytic, kinase-like 
region linked to a guanylyl cyclase. Th e 
receptor binds to both ANP and brain 
natriuretic peptide (BNP). Upon acti-
vation, the receptor mediates vasodi-
lation, increased urinary excretion of 
sodium and water, and suppression of 
myocardial hypertrophy and fi brosis.10 
Th us, the ANP/BNP–NPR-A signaling 
pathway may play a major role in con-
trolling blood pressure and extracellular 
fl uid volume, and VDR may be one of the 
upstream gatekeepers for this pathway.
VDR regulates other cardiovascular func-
tions
Could the ANP/BNP–NPR-A pathway 
fully account for the reduced CVD risk 
in stage 5 CKD patients receiving VDR 
modulator therapy? Perhaps not. Firstly, 
these fi ndings are mainly from in vitro cell 
culture studies with somewhat limited ani-
mal data. Secondly, the CVD problems in 
CKD are complex; decreased VDR activa-
tion may be just one of the many causal 
factors. Renal deficiency itself affects 
numerous elements in the cardiovascular 
pathophysiology, although the VDR sig-
naling pathway seems involved in several 
of these mechanisms (Figure 1). Th irdly, 
VDR aff ects diff erent functions that are 
linked to the cardiovascular system. For 
example, VDR modulators have been 
shown to downregulate renin,5 inhibit 
smooth muscle cell proliferation,11 restore 
uremia-induced endothelial-cell dysfunc-
tion,12 reduce left  ventricular hypertro-
phy,13 and so on. Any of these eff ects can 
also contribute to the cardiovascular ben-
efi ts of VDR modulator therapy. Simply 
put, the regulation of NPR-A may be one 
of several mechanisms by which VDR acti-
vation reduces CVD risk in CKD.
VDR-mediated autocrine/paracrine func-
tions
It is curious to note that, in the current 
study9 and also in previous reports from 
the same group,8,14,15 the maximal eff ects 
of calcitriol in inner medullary collecting 
duct cells, smooth muscle cells, or cardio-
myocytes are observed at relatively high 
doses (>1  nM), which are higher than 
the calcitriol concentration in circula-
tion (∼0.1  nM). Are there VDR-mediated 
autocrine and/or paracrine eff ects in the 
cardiovascular system? Previously it has 
been shown that various extrarenal cells 
and tissues express CYP27B1. It is also 
Figure 2 | VDR-mediated autocrine, endocrine, and paracrine effects. Calcitriol is well 
documented as an endocrine hormone. It may also work as an autocrine/paracrine factor in 
cardiovascular and other systems. Under normal conditions, many renal and extrarenal cells may 
be capable of generating calcitriol from 25(OH)D3. In chronic kidney disease (CKD), VDR-mediated 
endocrine, autocrine, and paracrine effects may be compromised. PTH, parathyroid hormone.
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Figure 1 | Hypothetical mechanisms for mortality related to cardiovascular disease in chronic 
kidney disease. Chronic kidney disease itself may affect many factors involved in regulation of 
mineral homeostasis, inflammation, thrombogenesis, vascular function, the renin–angiotensin–
aldosterone system (RAAS), and the atrial natriuretic peptide/brain natriuretic peptide (ANP/BNP)–
type A natriuretic peptide receptor (NPR-A) pathway. VDR may also play a key role in regulating 
several of these mechanisms.
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known that the level of 25(OH)D3 in circu-
lation is about ∼1000-fold higher than that 
of calcitriol. Th erefore, under normal con-
ditions, it is conceivable that many renal 
and extrarenal cells are capable of generat-
ing calcitriol from circulating 25(OH)D3 
to maintain a high local concentration of 
calcitriol for VDR-mediated autocrine 
and/or paracrine functions (Figure 2). 
However, this hypothesis raises more 
questions. For example, how does one 
investigate the signifi cance of these VDR-
mediated autocrine/paracrine functions 
in the cardiovascular system? Are these 
functions impaired in CKD? If yes, at what 
glomerular fi ltration rate does this mecha-
nism become impaired? Answers to these 
questions may help us further understand 
the benefi ts of VDR modulator therapy in 
reducing the CVD risk in CKD.
CONCLUSION
In summary, the paper by Chen et al.9 
provides interesting data showing that 
the regulation of NPR-A may be one of 
the mechanisms by which VDR activation 
is associated with cardiovascular benefi t 
in CKD.
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IgA nephropathy: Immune 
mechanisms beyond IgA mesangial 
deposition
A Rifai1
IgA nephropathy is attributable to mesangial IgA immune complex 
deposition. The pathogenic potential of frequently colocalized IgG 
deposits may depend on polarized T-helper cytokines that modulate 
Fcγ receptors of infiltrating macrophages, leading to either activation or 
inhibition that determines glomerular injury.
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In the complex web of potential mecha-
nisms implicated in the pathogenesis of 
IgA nephropathy, IgA glomerular depos-
its remain the sine qua non phenotype of 
the disease. Despite almost four decades 
of clinical and experimental investiga-
tions, the immunologic processes that 
induce and perpetuate glomerular IgA 
deposition remain a clinical challenge to 
identify. A decade after Jacque Berger’s 
seminal report of “IgA glomerular deposits 
in renal disease,” an experimental animal 
model was developed demonstrating that 
polymeric IgA immune complexes lead to 
IgA glomerular deposits. Th is was followed 
by a cascade of clinical investigations that 
reported IgA immune complexes in the cir-
culation and renal tissues of patients with 
IgA nephropathy. Now it is well recognized, 
as described in a comprehensive clinical 
review,1 that “primary IgA nephropathy is 
an immune-complex–mediated glomeru-
lonephritis defi ned immunohistologically 
by the presence of glomerular IgA deposits 
accompanied by a variety of histopatho-
logic lesions.” From this characterization it 
is implicit that not all IgA immune deposits 
possess equivalent pathogenic potential, as 
the glomerular landscape usually repre-
sents a wide spectrum that varies from 
minimal or no lesion to severe sclerosis. 
Th us, the enigma of glomerular IgA depo-
sition is wrapped in the mystery of absent 
correlation between the intensity of the 
IgA deposits and the extent of glomerular 
injury. Th e experimental fi ndings of Suzuki 
et al.2 (this issue) shed new investigative 
light to unwrap this mystery.
Over the years, several valuable experi-
mental models of IgA nephropathy have 
been developed that have provided 
insightful clues to the pathogenesis of 
the disease. Collectively, the experimen-
tal immunologic and histopathologic 
